Additionally, the 36-month beta value for CMPS is 2.28. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CMPS is 62.68M and currently, short sellers hold a 6.87% ratio of that float. The average trading volume of CMPS on February 04, 2025 was 1.04M shares.
CMPS) stock’s latest price update
Compass Pathways Plc ADR (NASDAQ: CMPS)’s stock price has increased by 6.61 compared to its previous closing price of 4.31. However, the company has seen a 16.62% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-01-21 that LONDON & NEW YORK–(BUSINESS WIRE)—- $CMPS #Biotech–Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by.
CMPS’s Market Performance
Compass Pathways Plc ADR (CMPS) has experienced a 16.62% rise in stock performance for the past week, with a 10.72% rise in the past month, and a -3.47% drop in the past quarter. The volatility ratio for the week is 9.11%, and the volatility levels for the past 30 days are at 10.61% for CMPS. The simple moving average for the past 20 days is 17.47% for CMPS’s stock, with a -25.81% simple moving average for the past 200 days.
Analysts’ Opinion of CMPS
Many brokerage firms have already submitted their reports for CMPS stocks, with RBC Capital Mkts repeating the rating for CMPS by listing it as a “Outperform.” The predicted price for CMPS in the upcoming period, according to RBC Capital Mkts is $23 based on the research report published on July 23, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CMPS reach a price target of $30. The rating they have provided for CMPS stocks is “Overweight” according to the report published on April 01st, 2024.
Deutsche Bank gave a rating of “Buy” to CMPS, setting the target price at $16 in the report published on December 12th of the previous year.
CMPS Trading at 11.02% from the 50-Day Moving Average
After a stumble in the market that brought CMPS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.96% of loss for the given period.
Volatility was left at 10.61%, however, over the last 30 days, the volatility rate increased by 9.11%, as shares surge +3.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.94% lower at present.
During the last 5 trading sessions, CMPS rose by +17.26%, which changed the moving average for the period of 200-days by -45.84% in comparison to the 20-day moving average, which settled at $3.91. In addition, Compass Pathways Plc ADR saw 21.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMPS starting from ATAI Life Sciences N.V., who sale 2,660,000 shares at the price of $6.05 back on Sep 26 ’24. After this action, ATAI Life Sciences N.V. now owns 6,905,774 shares of Compass Pathways Plc ADR, valued at $16,093,000 using the latest closing price.
Malievskaia Ekaterina, the 10% Owner of Compass Pathways Plc ADR, sale 8,900 shares at $7.91 during a trade that took place back on May 21 ’24, which means that Malievskaia Ekaterina is holding 3,931,687 shares at $70,379 based on the most recent closing price.
Stock Fundamentals for CMPS
Current profitability levels for the company are sitting at:
- -45.76 for the present operating margin
- 0.47 for the gross margin
The net margin for Compass Pathways Plc ADR stands at -39.27. The total capital return value is set at -0.76. Equity return is now at value -64.99, with -53.09 for asset returns.
Based on Compass Pathways Plc ADR (CMPS), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -3.23. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -37.61.
Currently, EBITDA for the company is -123.8 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 20.94. The receivables turnover for the company is 0.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.91.
Conclusion
In conclusion, Compass Pathways Plc ADR (CMPS) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
